The biopharmaceutical industry has witnessed rapid growth in recent years owing to increasing demand for sophisticated biologic drugs and therapies. Biopharma buffers play a crucial role in maintaining optimum pH levels during various stages of bioprocessing such as fermentation, cell culture, purification, and drug formulation. Common biopharma buffers include phosphate buffer saline (PBS), tris buffer saline (TBS), and citrate buffer saline (CBS). PBS buffer is widely used for washing, dilution, and storage of cells and antibodies. The global biopharma buffer market is estimated to be valued at US$3.68 Bn in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
The increasing demand for biopharmaceuticals is one of the major drivers fueling the growth of the biopharma buffer market. Rapid expansion of the biologics industry and growing pipeline of monoclonal antibodies and recombinant proteins have increased the consumption of bioprocessing buffers. Moreover, rising R&D investments by biopharma companies in cell and gene therapies is also contributing to the market growth. Innovation of novel buffer formulations to improve buffer efficacy is another key factor anticipated to open new avenues for the market players over the forecast period. For instance, in February 2022, Thermo Fisher launched its new CitratePro cell culture buffer designed for high cell density cultures.
SWOT Analysis
Strength: The biopharma buffer market has seen steady growth in recent years due to increasing demand for biopharmaceuticals. Manufacturers are developing innovative buffer solutions that improve stability, solubility, and shelf life of biologics. They provide customized buffers tailored to customers' specific needs.
Weakness: Developing new buffer formulations requires high R&D investment. Supply chain disruptions and raw material price volatility can impact production costs. Small manufacturers face challenges competing with large established players.
Opportunity: Growth in the biosimilars market and increasing demand in emerging economies present lucrative opportunities. Continued expansion of biomanufacturing capacities will augment buffer demand. Tailoring buffers for complex modalities like gene therapies can unlock new revenue streams.
Threats: Stringent regulatory norms increase compliance burden. Intense competition forces manufacturers to continuously innovate and lower prices. Industry consolidation may reduce choices for buffer suppliers.
Key Takeaways
The Global Biopharma Buffer Market Size is expected to witness high growth over the forecast period driven by rising demand for biologics.
Regional analysis: Asia Pacific is projected to be the fastest growing regional market for biopharma buffers owing to increasing biopharmaceutical production. Countries like China, India, South Korea and Singapore are expanding their biomanufacturing base which will boost buffer demand.
Key players: Key players operating in the biopharma buffer market are Avantor, Inc., ALKAN, Merck., XZL BIO-TECHNOLOGY CO., LTD, Bio-Rad Laboratories, Inc., BD., Promega Corporation., Thermo Fisher Scientific Inc. These companies are focusing on developing innovative buffer formulations and expanding their production capacities through organic and inorganic growth strategies to strengthen market position.
Get More Insights Here
